The symptomatic threshold for exacerbations and how treatments are likely to reduce the rate of exacerbations. a) Variations over time (solid line) and.

Slides:



Advertisements
Similar presentations
Evolution of ventilatory settings in randomised controlled trials investigating noninvasive ventilation in stable or post-exacerbation chronic obstructive.
Advertisements

The 20-year overall survival was significantly higher in the newborn screening (NBS) group than in the symptoms group for each of the subgroups defined.
Bland–Altman plot of projected apnoea threshold of measurement 1 versus 2. a) Rebreathing (R) method (n=20); b) steady-state (SS) method (n=18). Bland–Altman.
Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.
Correlation of excessive reactive oxygen species (ROS) production to clinical disease severity. Correlation of excessive reactive oxygen species (ROS)
Ventilatory and cerebrovascular responses to hyperoxic hypercapnia.
Flowchart for calculating the relative risk (RR) for cancer X and lung cancer (LC). Flowchart for calculating the relative risk (RR) for cancer X and lung.
Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %
Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.
A) Biological onset (inception), pre-clinical and clinical phases of the natural history of a disease. a) Biological onset (inception), pre-clinical and.
A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,
Survival without tracheostomy
Survey scores for Partners In Health (PIH-NL), Patient Activation Measure (PAM13-NL), Euroquol-5D3L (EQ-5D3L) and Short Self-Management Ability Scale (SMAS-s)
Symptoms measured by Edmonton Symptom Assessment Scale according to modified Medical Research Council (mMRC) dyspnoea scale groups. Symptoms measured by.
Effects of reslizumab on: (a) clinical asthma exacerbation (CAE) rates; (b) rates of clinical asthma exacerbation requiring oral corticosteroids (OCS);
Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.
A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.
Bland–Altman plot of slopes of measurement 1 versus 2
Bland–Altman comparison of lung clearance index (LCI) from multiple breath wash-out following open and modified closed circuit wash-in for both healthy.
SDS–PAGE and immunoblots of purified IgG for citrullination and carbamylation. a) Representative Coomassie-blue-stained isolated total IgG from patients.
Cluster diagram for four patient pairs with genotyped strains sharing the same sequence typing (ST). Cluster diagram for four patient pairs with genotyped.
Effects of reslizumab on asthma quality of life questionnaire (AQLQ) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.
Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.
Examination of the prevalence of asthma exacerbations and loss of asthma control throughout pregnancy in women with asthma. Examination of the prevalence.
Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.
a–h) Examples of short frenula in children and teenagers.
Forest plot displaying the effect estimates comparing azithromycin and placebo treatment in subgroups defined by above (>0.39 ng·mL−1) or below (
Effects of reslizumab on asthma control questionnaire-7 (ACQ-7) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.
A) White blood cell (WBC) counts for 10 lymphangioleiomyomatosis (LAM) patients (nine on sirolimus, one off sirolimus) experiencing pseudoneutropenia in.
A white elephant or the elephant in the room
Swimmer plots showing post-nivolumab progression-free survival for the three main drugs studied according to the line of treatment in which they were received.
Occurrence of morning symptoms
Kaplan–Meier curves of long-term survival in young (
Ethnic density distributions (%) by Middle Super Output Area mapped across south and east London for general practitioner-registered populations: a) Bangladeshi,
An audit of the post-hospitalisation pulmonary rehabilitation pathway in a northwest London hospital. An audit of the post-hospitalisation pulmonary rehabilitation.
The variability of probability of that the length of stay is longer than the median by country. The variability of probability of that the length of stay.
Comparison of absolute counts for a, b) white blood cells (WBC), c, d) neutrophils, e, f) monocytes, and g, h) eosinophils for 100 patients with lymphangioleiomyomatosis.
A) The flexible 1.9 mm diameter and 900 mm length cryoprobe, b) connected to the cryotherapy equipment. c) Marks on the distal area of the probe (1 cm.
Most frequent words and phrases based on user comments about the registry. Most frequent words and phrases based on user comments about the registry. Word.
Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to exacerbation history (intent-to-treat.
Usability statistics among top 10 tuberculosis (TB) units by transaction type for key data fields. Usability statistics among top 10 tuberculosis (TB)
Concentration of inflammatory cytokines in epithelial lining fluid (ELF) were plotted for the normal control, smoker normal forced oscillation technique.
Systems biology as a tool to improve idiopathic pulmonary fibrosis (IPF) treatment effectiveness. Systems biology as a tool to improve idiopathic pulmonary.
a) Mortality per time point (p<0
Specific therapeutic and prophylactic interventions to consider in different taxonomic groups of chronic obstructive pulmonary diseases (COPDs). Specific.
Venn diagram showing the overlap between the various spirometric definitions of airway obstruction and respiratory symptoms. **: p
Schematic overview of the suggested pharmacological management of chronic obstructive pulmonary disease (COPD). Schematic overview of the suggested pharmacological.
A family-based pulmonary rehabilitation (PR) programme enhanced the coping resources of the families of chronic obstructive pulmonary disease patients.
Patients' and partners' experience of anxiety in the Netherlands (NL) and Germany (GE), based on the Generalised Anxiety Disorder-single item questionnaire.
Individual plots of Standardised Asthma Quality of Life Questionnaire (AQLQ(S)) scores for the symptoms domain in each Global Initiative for Asthma level.
Forest plot of adjusted odds ratios (with 95% confidence intervals) from multivariable multinomial logistic regression analysis (table 4), by number of.
Receiver operating characteristic (ROC) curves (area under the curve (AUC) (95% CI)) for FACED (forced expiratory volume in 1 s, age, chronic colonisation.
Concordance of review article recommendations with contemporary guidelines. Concordance of review article recommendations with contemporary guidelines.
Weekly pneumococcal community-acquired pneumonia incidence rates over 5 years, with delineated school holiday periods by year. a) Year 1 (September 2008–2009).
Categorisation of social media posts related to chronic obstructive pulmonary disease (COPD). #: based on article ID, social media link and/or content.
Differences in a) functional residual capacity (FRC) and b) lung clearance index (LCI) when using all trials in comparison with only the first two trials.
Impact of dose adjustment in case of adverse drug reaction (ADR; includes dose interruption and/or reduction). a) No dose adjustment and b) dose adjustment.
Physician perspectives on self-administration of i. v. α1-antitrypsin
Distribution of patients in the first- or second-year follow-up according to the number of acute exacerbations of chronic obstructive pulmonary disease.
A–d) Bland–Altman plots of absolute differences between tremoFlo at 5 and 7 Hz versus the mean of the two measurements in resistance R and reactance X.
Percentage of culture-positive or PCR-positive sputum samples at stable state and exacerbation in year 1 and year 2 (full cohort, year 1 or year 2). a)
Bland–Altman comparison of functional residual capacity (FRC) measured from multiple breath wash-out following open and modified closed circuit wash-in.
Effect of the presence of aetiological factors (bacterial or viral infection, or eosinophilic inflammation) at stable visits on the odds of experiencing.
A response-adaptive platform trial may start by enrolling a broad patient population and randomise patients equally across a range of treatments, shown.
Comparison of cancer-specific survival in patients with nonsmall cell lung cancer detected incidentally by computed tomography (CT) (n=41) or chest radiography.
Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV1) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of.
Percentage of positive results by pathogen among study patients with identified pathogens. “Other” includes respiratory viruses, Stenotrophomonas, Prevotella,
Modified Delphi process used to reach a consensus among experts in severe asthma regarding the degree of benefit of biomarker-based adjustment of corticosteroid.
Signal intensity of Mycobacterium tuberculosis lipoarabinomannan in urine of children with tuberculosis (TB) in a high TB/HIV setting by ELISA at different.
Comparison of exhaled H2O2 values in chronic obstructive pulmonary disease (COPD) patients (n=12) and control group (n=9). a) Raw ambient air concentrations.
Presentation transcript:

The symptomatic threshold for exacerbations and how treatments are likely to reduce the rate of exacerbations. a) Variations over time (solid line) and how worsening exceeding the threshold (dotted horizontal line) are registered as exacerbations. b) Long-a... The symptomatic threshold for exacerbations and how treatments are likely to reduce the rate of exacerbations. a) Variations over time (solid line) and how worsening exceeding the threshold (dotted horizontal line) are registered as exacerbations. b) Long-acting broncho-dilators reduce symptoms by increasing the threshold at which patients perceive an exacerbation and how fewer exacerbations are registered as a result. c) Anti-inflammatory treatment may modulate inflammation and, thus, symptoms by reducing the amplitude of the symptomatic changes, resulting in fewer exacerbations. Jørgen Vestbo, and Peter Lange ERJ Open Res 2015;1:00011-2015 ©2015 by European Respiratory Society